The Rising Prevalence of Allergy-Causing Issues in the World Is Driving the Growth of the Global Allergy Immunotherapy Market

Allergy Immunotherapy Market

Allergy Immunotherapy Market, by Treatment Type (Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT)), by Allergy Type (Allergic Rhinitis, Allergic Asthma, Food Allergy, Venom Allergy, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Allergy immunotherapy, also known as allergen immunotherapy or allergy shots, is a treatment approach used to alleviate the symptoms and reduce the underlying cause of allergic diseases. It involves the administration of gradually increasing doses of specific allergens to desensitize the immune system and build tolerance to the allergens over time. This therapy is primarily used for the treatment of allergic rhinitis (hay fever), allergic asthma, and insect venom allergies.

Competitive Landscape:

Major players operating in the global allergy immunotherapy market include Dermapharm Holding SE, LETIPharma, Zhejiang Wolwo Bio-pharmaceutical Co., Ltd., HollisterStier Allergy, HAL Allergy B.V., Allergy Therapeutics, Stallergenes Greer, and ALK.

Key Market Drivers:

The rising prevalence of allergic diseases, such as allergic rhinitis, asthma, and food allergies, is expected to augment the growth of the global allergy immunotherapy market. The increasing burden of these conditions has led to a higher demand for effective and long-lasting treatments, driving market growth.

There is growing awareness among patients and healthcare professionals about the benefits of allergy immunotherapy. As people seek alternative treatments to manage allergies and reduce dependence on symptomatic medications, the demand for allergy immunotherapy is increasing, propelling the market growth.

Advancements in allergy immunotherapy treatments, such as the development of sublingual immunotherapy (SLIT) and new formulations, have expanded the options available to patients. These advancements have improved the safety, efficacy, and convenience of allergy immunotherapy. This is estimated to enhance the growth of the global allergy immunotherapy market. For instance, according to January 2023, HollisterStier Allergy launched Ultrafiltered Dog in order to diagnose and treat dog-sensitive individuals.

The trend toward personalized medicine and targeted therapies has influenced the allergy immunotherapy market. Allergy immunotherapy treatments can be tailored to individual patients based on their specific allergens, providing a more precise and effective treatment approach.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, there has been a heightened focus on respiratory health, as individuals with underlying respiratory conditions were more susceptible to severe COVID-19 outcomes. This increased awareness of respiratory health has led to a greater emphasis on managing and treating allergic respiratory conditions, boosting the demand for allergy immunotherapy. This boosted the growth of the global allergy immunotherapy market. For instance, in October 2022, Allergy Partners collaborated with Aimmune Therapeutics, in order to offer Palforzia, which is an oral immunotherapy.

Key Takeaways:

·         North America is expected to dominate the growth of the global allergy immunotherapy market, owing to the factors such as a high prevalence of allergies, advanced healthcare infrastructure, and a strong focus on research and development. The region is witnessing the adoption of novel allergy immunotherapy treatments, contributing to market growth. For instance, in June 2022, ALK introduced the phase I trial of its's sublingual tablet, which is used for treating peanut allergy.

·         Europe is estimated to witness high growth in the global allergy immunotherapy market. The region has a high burden of allergic diseases and a well-established healthcare system. The presence of key market players, favorable reimbursement policies, and increasing investments in research and development further contribute to market growth. For instance, in March 2022, Allergy Therapeutics partnered with ACG Biologics, in order to produce advanced peanut allergy vaccine candidates.